Friday, October 30, 2020 1:18:10 PM
Ok... I went back and read your posts... I apparently have confused you with another poster. My apology. That being said... I know you are a strong advocate for PR and its importance (and so am I), but I disagree that right now is the time for it. I strongly believe that we need to have our ducks in a row before being thrown out to the political and media wolves.
Once we are ready with the 102 patient data, manufacturing, and distribution, we will see at least an eua... and that will be a bombshell moment. Media coverage will come without trying. The drug will have a major impact on ICUs around the country and then the world. Heck... we might even see news about how much news we are getting (jk).
So if you still disagree, I get it. But PR and media coverage right now isn't necessary... actually, i think it would be extremely difficult to proceed with all our necessary preparations when the whole world is begging for the drug.
Once we are ready with the 102 patient data, manufacturing, and distribution, we will see at least an eua... and that will be a bombshell moment. Media coverage will come without trying. The drug will have a major impact on ICUs around the country and then the world. Heck... we might even see news about how much news we are getting (jk).
So if you still disagree, I get it. But PR and media coverage right now isn't necessary... actually, i think it would be extremely difficult to proceed with all our necessary preparations when the whole world is begging for the drug.
Disclaimer: I am not a professional advisor. Seek professional advice before investing or trading. I take risky positions and do not advise anyone to follow my opinions or actions.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
